+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial



Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial



Journal of Clinical Oncology 21(17): 3207-3213



To compare the survival benefit obtained with cisplatin plus gemcitabine, a cisplatin-based triplet, and nonplatinum sequential doublets in advanced non-small-cell lung cancer (NSCLC). Stage IIIB to IV NSCLC patients were randomly assigned to receive cisplatin 100 mg/m2 day 1 plus gemcitabine 1,250 mg/m2 days 1 and 8, every 3 weeks for six cycles (CG); cisplatin 100 mg/m2 day 1 plus gemcitabine 1,000 mg/m2 and vinorelbine 25 mg/m2 days 1 and 8, every 3 weeks for six cycles (CGV); or gemcitabine 1,000 mg/m2 plus vinorelbine 30 mg/m2 days 1 and 8, every 3 weeks for three cycles, followed by vinorelbine 30 mg/m2 days 1 and 8 plus ifosfamide 3 g/m2 day 1, every 3 weeks for three cycles (GV-VI). Five hundred fifty-seven patients were assigned to treatment (182 CG, 188 CGV, 187 GV-VI). Response rates were significantly inferior for the nonplatinum sequential doublet (CG, 42%; CGV, 41%; GV-VI, 27%; CG v GV-VI, P =.003). No differences in median survival or time to progression were observed. Toxicity was higher for the triplet: grade 3 to 4 neutropenia (GC, 32%; CGV, 57%; GV-VI, 27%; P <.05); neutropenic fever (CG, 4%; CGV, 19%; GV-VI, 5%; P <.0001); grade 3 to 4 thrombocytopenia (CG, 19%; CGV, 23%; GV-VI, 3%; P =.0001); and grade 3 to 4 emesis (GC, 22%; GCV, 32%; GV-VI, 6%; P <.0001). On the basis of these results, CG remains a standard regimen for first-line treatment of advanced NSCLC.

(PDF emailed within 0-6 h: $19.90)

Accession: 048526995

Download citation: RISBibTeXText

PMID: 12947054

DOI: 10.1200/jco.2003.12.038


Related references

Cisplatin/gemcitabine vs cisplatin/gemcitabine/vinorelbine vs sequential doublets of gemcitabine/vinorelbine followed by ifosfamide/vinorelbine in advanced non-small cell lung cancer Final results of a Spanish lung cancer group phase III trial. European Journal of Cancer 37(Suppl. 6): S28, 2001

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Annals of Oncology 21(3): 556-561, 2010

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. Journal of Clinical Oncology 17(11): 3522-3530, 1999

Cisplatin/etoposide versus cisplatin/vinorelbine versus cisplatin/paclitaxel in advanced non-small cell Lung cancer A phase III randomized trial. European Respiratory Journal 12(SUPPL 28): 8S, Sept, 1998

ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Cancer Research and Treatment 49(3): 678-687, 2016

1190Pa Randomized Phase Ii Trial Of Cisplatin Plus Gemcitabine Versus Carboplatin Plus Gemcitabine In Patients With Completely Resected Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (Hot0703). Annals of Oncology 25(Suppl_4): iv414-iv415, 2014

Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology 5(10): 1602-1608, 2011

Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. Lung Cancer 52(1): 75-81, 2006

A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study). Journal of Thoracic Oncology 4(3): 364-370, 2009

Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. Journal of Clinical Oncology 18(7): 1451-1457, 2000

A randomized phase II trial of sequential gemcitabine plus vinorelbine followed by gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung Cancer 57(2): 168-174, 2007

Teniposide/cisplatin versus paclitaxel/cisplatin in advanced non-small cell lung cancer Interim results of a randomized phase III study of the EORTC lung cancer cooperative group. European Respiratory Journal Suppl. 9(23): 399S-400S, 1996

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. Journal of Clinical Oncology 18(1): 122-130, 2000

Randomized clinical trial of paclitaxel plus cisplatin versus gemcitabine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 10(2): 141-143, 2007

Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. Journal of Clinical Oncology 23(13): 2937-2945, 2005